NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 298)
Posted On: 12/01/2020 4:31:17 PM
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Upcoming Acclaim-1 Clinical Trial
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, on Monday announced its commencement of clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). The company’s timing of patient recruitment and enrollment keeps it on track for its Acclaim-1 clinical trial to commence in the first-half of 2021. “Our clinical team is engaging with prestigious cancer centers and research institutions across the U.S. to ensure we select optimal study sites, which play an important role in the success of a clinical trial,” said Rodney Varner, president and chief executive officer of Genprex. “We look forward to working with leading clinical investigators who will help drive our mission to bring forth a treatment for advanced lung cancer patients.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, on Monday announced its commencement of clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). The company’s timing of patient recruitment and enrollment keeps it on track for its Acclaim-1 clinical trial to commence in the first-half of 2021. “Our clinical team is engaging with prestigious cancer centers and research institutions across the U.S. to ensure we select optimal study sites, which play an important role in the success of a clinical trial,” said Rodney Varner, president and chief executive officer of Genprex. “We look forward to working with leading clinical investigators who will help drive our mission to bring forth a treatment for advanced lung cancer patients.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Genprex Inc. (GNPX) Stock Research Links
Scroll down for more posts ▼